Abstract
In the metabolic syndrome (MS), a condition that associates three or more pathologies such as hypertension, central obesity, type II diabetes, insulin resistance and dyslipidemias, the kidneys are severely affected. The pathological alterations in the kidneys, associated with MS, may be modified by sex hormone levels. In general, estrogens are a protection against the development of cardiovascular and renal diseases in humans and experimental models, but androgens may have an opposite effect. Among the metabolic systems that can be modulated by sex hormones in the kidney, the more important are: renin-angiotensin-aldosterone system, arachidonic acid metabolism, nitric oxide system and renal extracellular matrix proteins. These are metabolic pathways normally associated, in order to maintain the most efficient functioning of renal hemodynamics. There is a close interrelationship between sex hormones and some pathways involved in the metabolic syndrome; also pathways can modulate each other. The circulating concentrations of hormones may determine the degree of overall pathological alterations in the syndrome.
Keywords: sclerosis, infiltration of inflammatory cells, nitric oxide system, arachidonic acid metabolism, renin-angiotensin-aldosterone system, cardiovascular and renal diseases, estrogens, dyslipidemias, insulin resistance, type II diabetes, central obesity, hypertension, kidney, sex hormones, Metabolic syndrome
Current Topics in Medicinal Chemistry
Title: Sex Hormones, Metabolic Syndrome and Kidney
Volume: 11 Issue: 13
Author(s): G. Banos, V. Guarner, M. El Hafidi and I. Perez-Torres
Affiliation:
Keywords: sclerosis, infiltration of inflammatory cells, nitric oxide system, arachidonic acid metabolism, renin-angiotensin-aldosterone system, cardiovascular and renal diseases, estrogens, dyslipidemias, insulin resistance, type II diabetes, central obesity, hypertension, kidney, sex hormones, Metabolic syndrome
Abstract: In the metabolic syndrome (MS), a condition that associates three or more pathologies such as hypertension, central obesity, type II diabetes, insulin resistance and dyslipidemias, the kidneys are severely affected. The pathological alterations in the kidneys, associated with MS, may be modified by sex hormone levels. In general, estrogens are a protection against the development of cardiovascular and renal diseases in humans and experimental models, but androgens may have an opposite effect. Among the metabolic systems that can be modulated by sex hormones in the kidney, the more important are: renin-angiotensin-aldosterone system, arachidonic acid metabolism, nitric oxide system and renal extracellular matrix proteins. These are metabolic pathways normally associated, in order to maintain the most efficient functioning of renal hemodynamics. There is a close interrelationship between sex hormones and some pathways involved in the metabolic syndrome; also pathways can modulate each other. The circulating concentrations of hormones may determine the degree of overall pathological alterations in the syndrome.
Export Options
About this article
Cite this article as:
Banos G., Guarner V., El Hafidi M. and Perez-Torres I., Sex Hormones, Metabolic Syndrome and Kidney, Current Topics in Medicinal Chemistry 2011; 11 (13) . https://dx.doi.org/10.2174/156802611796117577
DOI https://dx.doi.org/10.2174/156802611796117577 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
1h Post-load Blood Glucose in the Identification of Proatherogenic Cardiometabolic Profile in Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Modern Drug Discovery Technologies: Opportunities and Challenges in Lead Discovery
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects
Current Neuropharmacology The Role of microRNAs in Cardiovascular Disease
Current Medicinal Chemistry Transmucosal Drug Delivery- An Overview
Drug Delivery Letters Mean Platelet Volume During Ischemic Stroke is a Potential Pro-inflammatory Biomarker in the Acute Phase and During Neurorehabilitation Not Directly Linked to Clinical Outcome
Current Neurovascular Research Editorial [Hot Topic:The Calcium-Sensing Receptor: Pathophysiology and Pharmacological Modulation(Guest Editor: Ubaldo Armato)]
Current Pharmaceutical Biotechnology Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Fitness or Fatness - the Debate Continues for the Role of Leptin in Obesity-Associated Heart Dysfunction
Current Diabetes Reviews Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Anemia in Chronic Heart Failure - Clinical and Prognostic Significance
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Genetic Basis, Nutritional Challenges and Adaptive Responses in the Prenatal Origin of Obesity and Type-2 Diabetes
Current Diabetes Reviews Statins Therapy may Change a Course of Lung Fibrosis and Pulmonary Hypertension: A New Indication for Therapy or Just “Statinomania”?
Current Respiratory Medicine Reviews